Revenue

FY 2025

$9.425B – $9.575B "

$9.45B – $9.6B "

raised

Organic operational revenue growth

FY 2025

6% – 8% "

6.5% – 8% "

raised

Adjusted Net Income

FY 2025

$2.775B – $2.825B "

$2.825B – $2.875B "

raised

Adjusted Diluted EPS

FY 2025

$6.20 – $6.30 "

$6.30 – $6.40 "

raised

Reported Diluted EPS

FY 2025

$5.85 – $5.95 "

$5.90 – $6.00 "

raised

Triple Combination Parasiticides

Consistently highlighted for their first‐mover advantage and fast‐growing market. Q1 2025 mentioned strong market leadership with discussions on first-mover advantage and expanding share in puppies. " Q4 2024 focused on market size and growth expectations (e.g., doubling by 2028) along with expanded market share. " " " Q3 2024 reinforced leadership with increased prescription rates and substantial market share gains. " " " "

Q2 2025 reinforced the leadership of triple combination products with details on 20% operational revenue growth, a further increase in market share (from 30% to 45%), and high adoption with 60% of puppies placed immediately on triple combinations. " " " "

The topic is consistently positive with an ongoing narrative of leadership, growing market share, and rising adoption. The sentiment remains upbeat with more detailed metrics in Q2 2025, suggesting steady momentum.

Simparica Trio

Across previous periods, Simparica Trio was portrayed as the leading product with robust revenue contributions, strong patient retention, and clear differentiation. Q1 2025 emphasized its growth and first-mover status. " Q4 2024 highlighted its phenomenal revenue (exceeding $1B globally) and continued market lead. " " " Q3 2024 underscored its top prescribed status and continued gains in prescription growth. " " " "

In Q2 2025, Simparica Trio continues to be positioned strongly as the leader in the triple combination space, backed by impressive operational revenue growth and the successful expansion of alternative channels. " "

The sentiment remains uniformly positive with continuous reinforcement of first-mover advantage and market leadership. There is an increased focus on operational metrics and alternative channels, indicating further consolidation of its market position.

Robust and Diverse Pipeline

Previous calls emphasized a strong focus on the osteoarthritis pain franchise with products like Librela and Solensia. Q1 2025 focused on double-digit growth and incremental pipeline innovation with an emphasis on OA. " Q4 2024 broadening the discussion to include oncology, renal, and long-acting formulations, and Q3 2024 reiterated transformational OA treatments with less emphasis on non-OA areas. " " " " " "

Q2 2025 expanded the narrative by highlighting upcoming blockbuster products across multiple areas (OA pain with a new long-acting mAb, as well as renal, oncology, and even hints at cardiology opportunities) that bolster the innovation-driven growth strategy. " " " "

While OA remains the core, the current period shows a broadened focus toward diversifying the pipeline into additional therapeutic areas. This indicates an evolution from a predominantly OA focus to a more diversified and innovation-rich pipeline, suggesting an optimistic outlook for future growth.

Librela Adoption Challenges and Label Change Impact

In Q4 2024, Librela was described in a positive light with strong sales and impressive market penetration despite initial limited targeting (severe cases). " " In Q1 2025, discussions centered on a slower-than-expected uptake in certain segments and emphasized actions such as increased medical education, real-world studies, and targeted campaigns. " " " " Q3 2024 did not mention adoption challenges, instead highlighting strong performance and high penetration. " " "

Q2 2025 brought out the challenges explicitly by noting sluggish patient uptake despite high satisfaction, along with veterinarian concerns and a focus on upcoming label changes for a new long-acting OA product. There is an explicit mention of investing in better clinical data and education to overcome these headwinds. " " " "

The sentiment has shifted in recent periods. While earlier periods (especially Q3 and Q4) showed strong adoption stories, Q1 and especially Q2 now report more challenges with slower uptake and the need for strategic initiatives like improved education and third-party studies. This suggests a slight softening of sentiment and a proactive approach to address adoption issues.

Expanding Alternative Channel Strategy

Earlier periods highlighted the importance of alternative channels. In Q3 2024, the strategy was noted for driving growth with a 34% YoY increase and contributing around 15–20% of U.S. sales. " " Q4 2024 mentioned that alternative channels (retail, online, home delivery) were increasingly important to the portfolio. " Q1 2025 showed strong growth in retail (40% growth and around 21% share) and emphasized diversification. "

Q2 2025 reinforced the role of alternative channels by noting that they account for 22% of the U.S. companion animal revenue, highlighting consistent growth (25–30%) and stocking activity in retail. The emphasis on improved compliance and customer convenience through these channels was maintained. " "

The trend remains consistently positive with steady, incremental gains. The narrative underscores that alternative channels are becoming an even more integral part of the omnichannel strategy, solidifying their role in sales diversification and compliance enhancement.

Evolving Competitive Pressures

Previous periods (Q1, Q3, and Q4 2024) consistently addressed competitive pressures across parasiticides and dermatology. Q1 2025 discussed competition in parasiticides and the shift from single therapies to combinations. " " Q3 2024 and Q4 2024 noted competitive entrants while emphasizing first-mover advantage and durable leadership in both parasiticides and dermatology. " " " " " " " "

Q2 2025 continued to detail evolving competitive dynamics by comparing parasiticides, dermatology, and historical APOQUEL focus. It highlighted strong performance in parasiticides and steady growth in the dermatology franchise despite continued competitive pressure, with minimal patient share loss in key areas. " "

The overall sentiment remains resilient. Although competitive pressures intensify over time, Zoetis regularly reiterates its first-mover advantage, strong brand loyalty, and market leadership to counter these pressures, indicating sustained confidence in maintaining growth despite increased competition.

Tariff, Trade Policy, and FX Uncertainties

In Q1 2025, there was discussion on managing tariffs (especially with API imports) and favorable FX adjustments due to currency movements. " " " Q4 2024 focused on the headwinds posed by a strong U.S. dollar and noted potential policy changes that were not yet factored into guidance. " " Q3 2024 had limited mention aside from operational results excluding FX impacts. " "

Q2 2025 discussed tariffs and trade policy in detail, noting that current tariff impacts are slightly higher than previously estimated but are absorbable through improved margins driven by lower manufacturing costs and effective expense management. FX impacts, as per updated guidance, continue to be managed confidently. " "

The narrative remains cautious but well-managed. Macroeconomic uncertainties regarding tariffs, trade policy, and FX persist over periods, though Zoetis’s ability to absorb these impacts is consistently highlighted. The discussion in Q2 is more detailed, reflecting an ongoing awareness and proactive management of these external risks.

Dermatology Franchise Dynamics

In Q1 2025, the dermatology franchise was portrayed as robust with strong revenue growth, leveraging high satisfaction rates and conversion to Apoquel Chewable. " " " Q3 2024 emphasized long-standing safety (11 years) and strong market performance with continued investments in direct-to-consumer advertising. " " Q4 2024 noted solid operational growth and highlighted the substantial market opportunity given untapped patient populations. " "

Q2 2025 reiterated healthy performance with $460 million global revenue and 11% operational growth. It also emphasized key drivers such as the complementary roles of Apoquel and Cytopoint, sustained compliance, and successful leveraging of alternative channels to mitigate competitive pressures. " " " "

The sentiment remains consistently strong across periods, with robust underlying growth despite intensifying competition. The focus remains on expanding market share, improving compliance, and leveraging product differentiation to drive growth. There is a reaffirmed commitment to innovation and tapping into the untapped market of under‑treated patients.

Declining Veterinary Clinic Visits

Q3 2024 acknowledged a decline in overall clinic visits but noted that therapeutic visits (e.g., for OA pain and dermatology) were increasing, and alternative channels were offsetting the decline. " Q4 2024 admitted to a decline in visits yet highlighted healthy average spend per visit and stronger pain-related therapeutic visits. " " Q1 2025 did not address it directly.

Q2 2025 did not specifically discuss declining clinic visits; instead, the emphasis was on improved vet clinic activity relative to earlier lows, suggesting a recovery or stabilization compared to prior periods. "

While clinic visits had been a concern in earlier periods, the current period shows improvement compared to previous lows. The focus continues to shift toward alternative channels and therapeutic visits, mitigating the impact of declining overall clinic visits on prescription growth.

APOQUEL Emphasis

In Q3 2024, APOQUEL was noted for its strong performance (16% growth, 11 years of safety) and remained a focal point in the dermatology portfolio. " " Q1 2025 reinforced strong patient retention and conversion to the chewable form, underscoring its long-term positioning. " Q4 2024 integrated APOQUEL as a key driver within the dermatology franchise and highlighted its market contribution with a balanced channel strategy. " "

Q2 2025 did not indicate any reduced emphasis on APOQUEL. Rather, the discussion maintained focus on its differentiation (long-term safety and ease of administration) alongside investments in complementary products within the dermatology suite. "

There is no notable reduction in emphasis on APOQUEL across periods. The messaging remains consistent, with APOQUEL continuing to be recognized as a core asset in the dermatology franchise. The focus has shifted to a balanced portfolio approach rather than de-emphasizing any single product.